Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

At the prior data cutoff (February 9, 2017) the ALEX trial showed superior investigator-assessed progression-free survival (PFS) for alectinib versus crizotinib in untreated, anaplastic lymphoma kinase (ALK)-positive, advanced NSCLC (hazard ratio = 0.47, 95% confidence interval: 0.34–0.65, p < 0....

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2019-07, Vol.14 (7), p.1233-1243
Main Authors: Camidge, D. Ross, Dziadziuszko, Rafal, Peters, Solange, Mok, Tony, Noe, Johannes, Nowicka, Malgorzata, Gadgeel, Shirish M., Cheema, Parneet, Pavlakis, Nick, de Marinis, Filippo, Cho, Byoung Chul, Zhang, Li, Moro-Sibilot, Denis, Liu, Ting, Bordogna, Walter, Balas, Bogdana, Müller, Barbara, Shaw, Alice T.
Format: Article
Language:English
Subjects:
Alectinib
ALEX
EML4-ALK
NGS
Non–small cell lung cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!